EmbectaMEX:EMBC 53 Days Payable is 73.63 as of Mar. 2026, which is 36% above its 10-year median of 54.32. GuruFocus rates MEX:EMBC with a GF Score™ of 53/100 and a GF Value™ of MXN1,817.27. The stock has 6 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Embecta ranks worse than 54.65% on this metric.
Embecta's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN1,368 Mil. Embecta's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN1,695 Mil.
Hence, Embecta's Days Payable for the
three
months ended in Mar. 2026 was 73.63.
The historical rank and industry rank for Embecta's Days Payable or its related term are showing as below:
MEX:EMBC'
s Days Payable Range Over the Past 10 Years
Min: 46.7 Med: 54.32 Max: 74.7
Current: 63.69
During the past 7 years, Embecta's highest Days Payable was 74.70. The lowest was 46.70. And the median was 54.32.
MEX:EMBC's Days Payable is ranked worse than 54.65% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs MEX:EMBC: 63.69
Embecta's Days Payable
increased
from Mar. 2025 (64.05) to Mar. 2026 (73.63).
It may suggest that Embectadelayed paying its suppliers.
Embecta Days Payable Related Terms
Embecta Days Payable Historical Data
* Premium members only.
The historical data trend for Embecta's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:EMBC vs PDEX, STXS, SMTI: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Embecta's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embecta Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embecta's Days Payable distribution charts can be found below:
* The bar in red indicates where Embecta's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Embecta's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embecta (MEX:EMBC) has a Days Payable of 73.63 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Embecta and its competitors. This is 36% above median its historical median of 54.32. Over the past decade, Embecta's Days Payable has ranged from 46.70 to 74.70. According to the industry distribution chart, Embecta ranks #435 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 54.6%.
Is Embecta's Days Payable too high?
Embecta's current Days Payable of 73.63 is 36% above median its 10-year median of 54.32. Over the past 10 years, this metric has ranged from a low of 46.70 to a high of 74.70. The Medical Devices & Instruments industry median Days Payable is 68.14. Embecta's value of 73.63 is 8.1% above this industry median. Based on the distribution chart, Embecta ranks #435 out of 796 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Embecta has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Embecta's Days Payable compare to PDEX and STXS?
According to the Medical Devices & Instruments industry distribution chart, Embecta ranks #435 out of 796 companies for Days Payable. This places Embecta in the lower half of its industry. The industry median Days Payable is 68.14. Embecta's value of 73.63 is 8.1% above this benchmark. Historically, Embecta's own Days Payable has ranged from 46.70 to 74.70 over the past decade. While the company's 10-year median is 54.32 vs. the industry median of 68.14, Embecta has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embecta's current Days Payable of 73.63 is 8.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Embecta and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embecta's current Days Payable is 73.63, which is 36% above median its own 10-year median of 54.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Embecta (MEX:EMBC) has a current Days Payable of 73.63. The stock's GF Value™ is MXN1,817.27, compared to a current price of MXN497.96 — trading 72.6% below its estimated fair value. The current Days Payable is 73.63, which is 36% above median its 10-year median of 54.32 and 8.1% above the Medical Devices & Instruments industry median of 68.14. Embecta's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Embecta (MEX:EMBC), the current Days Payable is 73.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embecta (MEX:EMBC) Overvalued in 2026?
Based on GuruFocus' analysis, Embecta stock appears to be undervalued.
The current stock price of MXN497.96 is trading 72.6% below its estimated GF Value™ of MXN1,817.27.
Key valuation signals for MEX:EMBC:
Days Payable: 73.63 (36% above median its 10-year median of 54.32)
GF Value™: MXN1,817.27 vs. price of MXN497.96 (72.6% below fair value)
Industry Position: 8.1% above the Medical Devices & Instruments median (#435 of 796)
No single metric tells the full story. See the MEX:EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
53GF Score
Get the complete analysis for MEX:EMBC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:EMBC has been successfully added to your 
